Once picked as a $500M winner, bankrupt Achaogen auctions off its an...

06/07/19

Once picked as a $500M winner, bankrupt Achaogen auctions off its antibiotic for a fraction of that  Endpoints News

In a boost to Rituxan franchise, Roche nabs quick approval for polatuzumab vedotin. Roche's latest antibody-drug conjugate has crossed the FDA finish line, ...

[more]